TBXT and lung carcinoma: In the lung cancer animal model, we observed 26.88% and 33.76% decrease in the level of the carbonyl content with the treatment of PFT-HSA-TFT-Cy7 at 1 μM and 3 μM while 31.55% and 44.54% decrease in the carbonyl content in the presence of PFT-Hcy-HSA-Cy7 at 1 μM and 3 μM. On the other hand, in the glycation animal model, we observed 39.14% and 42.90% inhibition of the carbonyl content with the treatment of PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 at 5 μM (Figure 2(a)).